



LKT Laboratories, Inc.

GDC-0032

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID G1308

CAS No. 1282512-48-4

Chemical Name 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide

Synonym GDC0032, Taselisib

Formula C₂₄H₂₈N₈O₂

Formula Wt. 460.53

Melting Point


Purity ≥98%

Solubility DMSO 70 mg/mL warmed (151.99 mM)
Water Insoluble
Ethanol Insoluble warmed

Store Temp -20°C

Ship Temp Ambient

Description GDC-0032 inhibits PI3K, exhibiting anticancer chemotherapeutic activity by inhibiting tumor growth in various animal models. This compound also induces G0/G1 phase cell cycle arrest in models of uterine serous carcinoma.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
G1308	1 mg	\$45.00
G1308	5 mg	\$98.00
G1308	25 mg	\$250.00

References Lopez S, Schwab CL, Cocco E, et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. *Gynecol Oncol.* 2014 Nov;135(2):312-7. PMID: 25172762.

Ndubaku CO, Heffron TP, Staben ST, et al. Discovery of 2-[3-[2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl]-2-methylpropanamide (GDC-0032): a 8-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. *J Med Chem.* 2013 Jun 13;56(11):4597-610. PMID: 23662903.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.